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Escherichia coliO157:H7 is themain causative agent of haemolytic uremic syndrome. Cattle are themain reservoir of these bacteria,
and have been shown to develop immune response to colonization. Our aim was to investigate the faecal shedding pattern of E. coli
O157:H7 in calves challenged intragastrically with either 108 or 1010 CFU, as well as the ability of specific preexisting antibodies to
reduce shedding of the pathogen. Shedding was analysed by direct counting as well as enrichment of rectoanal mucosal swabs.
Statistical analysis was performed using a linear model for repeated measures with and without the inclusion of preexisting
antibodies against the carboxy-terminal fraction of intimin-𝛾 (𝛾-intimin C280) as a covariable. Results suggest that there is a
statistical difference in the area under the shedding curves between both doses for 14 as well as 28 days after challenge (p = 0.0069
and 0.0209, resp.).This difference is increased when the prechallenge antibodies are taken into account (p = 0.0056 and 0.0185). We
concluded that the bacterial dose influences shedding on calves experimentally challenged and that preexisting antibodies against
E. coli O157:H7 𝛾-intimin C280 could partially reduce faecal excretion.
1. Introduction
Enterohaemorrhagic Escherichia coli (EHEC) O157:H7 is a
major etiologic agent of diseases in humans, whose clini-
cal spectrum includes diarrhoea, haemorrhagic colitis, and
haemolytic uremic syndrome (HUS), the leading cause of
chronic renal failure in children in Argentina and several
other countries [1, 2].
Cattle are the main reservoir of EHEC O157:H7, which
predominately colonizes the lymphoid follicle-dense mucosa
at the terminal rectum and the rectoanal junction (RAJ) [3].
Faecal contamination ofmeat during slaughter, the use of raw
faeces as fertilizers, and the contamination of drinking water
are the major ways by which this microorganism can enter
the human food chain [4–6].
This bacterium produces Shiga toxins types 1 and/or 2 [7–
9], which are responsible for systemic damage, particularly of
the vascular endothelium of kidneys and brain, with severe
renal and neurological sequelae in children and the elderly. In
addition to Shiga toxins, E. coli O157:H7 is characterized by
other virulence-associated traits which enables it to colonize
the intestinal mucosa of humans and animals with a char-
acteristic histopathological lesion known as “attaching and
effacing” (A/E). A large chromosomal pathogenicity island
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called Locus of Enterocyte Effacement (LEE) is associated
with A/E activity [10–12]. The LEE encodes a type three
secretion system (TTSS) that translocates effector proteins
responsible for the A/E lesion into the host cell. Intimin, a
bacterial outer membrane protein, binds to Tir, the translo-
cated intimin receptor in the host cell membrane, and
this binding leads to the formation of the A/E lesion. Tir,
EspB, and other LEE-encoded proteins are translocated into
the host cell through a transiently produced filamentous
structure [13], which consists of an assembly of EspA subunits
[14] and contributes, in turn, to the creation of a pore in the
eukaryotic cell membrane.
Ample evidence suggests that infected animals can
excrete the bacteria in their faeces from a few days to months
[6, 15]. Key features associated with the rate of colonization
are the age of the animals and genetic markers in the
pathogen.
Many virulence factors of E. coli O157:H7 induce an
immune response during the course of natural as well as
experimental infections in cattle. Oral inoculation of calves
and steers withE. coliO157:H7 promotes an increase in serum
antibody titres against the O157 lipopolysaccharide and neu-
tralizing antibodies to Shiga toxins. Recently, Bretschneider
et al. [16] demonstrated that cattle respond serologically to
Intimin and EspB of E. coli O157:H7 during the course of
experimental infection. Furthermore, several authors have
reported that calves and cattle shed fewer bacteria after
several experimental inoculations, which could be related to a
partially protective immune response elicited by the pathogen
[17–19].
Vaccination is one of the preslaughter interventions that
shows promise to reduce EHEC O157:H7 occurrence in
cattle. We, along with other groups, have demonstrated that
vaccination of calves with type three secretion injection
apparatus proteins results in reduced excretion of EHEC
O157:H7 after experimental infection in cattle with an oral
challenge dose of 1010 CFU [20–23].
We therefore assessed if the level of colonization depends
on the bacterial challenge dose and whether previous anti-
bodies against the carboxy-terminal fraction of 𝛾-intimin (𝛾-
intimin C280) could reduce faecal excretion of the pathogen.
Furthermore we assessed the humoral immune response
elicited in response to the challenge. For this purpose, we
compared the effect of two different doses of oral inoculation
in calves regarding the colonization status and the associated
serum immune response with shedding.
2. Materials and Methods
2.1. Animals. Nine four-month-old conventionally reared
Holando-Argentino male calves were obtained from a dairy
farm in Buenos Aires Province, Argentina, and housed in
biosafety level 2 containments rooms at the InstitutoNacional
de Tecnologı´a Agropecuaria (INTA) Experimental Station.
All calves were acclimatized to the containments room for 1
week prior to the challenge and were deemed healthy by clin-
ical examination and treated prophylactically upon arrival
with 1% ivermectin to control intestinal nematodes. Calves
were fed alfalfa pellets, with free access to hay and water.
Prior to the challenge, calves were confirmed twice (one
month and three days before inoculation) to be negative for
E. coli O157:H7 by enrichment of rectoanal mucosal swabs
followed by immunomagnetic separation, and serum specific
antibodies were also assessed as described below. All animal
experiments were performed with the approval of the INTA
Animal Welfare Committee.
2.2. Strain. The challenge strain of E. coli O157:H7 selected
for the experimental infectionwas 438/99.This strainwas iso-
lated from a healthy cow and was used previously in experi-
mental studies [22]. It was selected for spontaneous resistance
to nalidixic acid to facilitate recovery from rectoanal mucosal
swabs and tissues and possesses the genes for enterohe-
molysin, 𝛾-intimin, EspA, EspB, Stx2, and the pO157 plasmid.
2.3. Experimental Infection. Animals were randomly
assigned to Groups 1 (𝑛 = 5) and 2 (𝑛 = 4) and challenged
intragastrically with the bacterium. Group 1 received
108 CFU, whereas Group 2 was challenged with a dose of
1010 CFU of E. coli O157:H7 strain 438/99 in 15mL of sterile
PBS. Randomization was performed to assure that both
groups were composed of animals with similar weight dis-
tribution (approximately 100 and 120 kg, resp.).
2.4. Sample Collection. Rectoanal mucosal swabs were taken
at 0, 2, 5, 8, 11, 14, 17, 20, 24, and 28 days after the challenge [24].
In addition, serum samples were taken at 0, 8, 17, and 28 days
after the oral bacterial challenge. Necropsy was performed
at day 28 after challenge and tissue sections from the ileum,
cecum, and rectoanal junction were obtained and evaluated
for the presence of bacteria and mucosal antibodies and for
histopathology.
One animal from Group 2 was euthanized 20 days after
the challenge for health issues according to the INTAAnimal
Welfare Committee standards.
2.5. E. coli O157:H7 Shedding. The magnitude and duration
of the fecal excretion of viable E. coli O157:H7 were fol-
lowed by culture of rectoanal mucosal swabs, as previously
described [25]. Briefly, bacterial CFU/swab was determined
by vortexing the swabs in Trypticase soy broth (TSB, Oxoid,
Basingstoke, UK), plating serial dilutions on Sorbitol Mac-
Conkey agar (Oxoid, Basingstoke, UK) containing 20𝜇g/mL
nalidixic acid (Sigma, St. Louis, USA), 2.5 𝜇g/mL potassium
tellurite, and 0.05 𝜇g/mL cefixime (CT-SMAC). When direct
cultures were negative, swabs were enriched at 37∘C for
18 h and 1mL of this culture was subjected to E. coli O157
immunomagnetic separation (IMS) performed according to
the manufacturer’s instructions (Dynabeads anti-E. coliO157,
Invitrogen Dynal AS, Oslo, Norway). The bead-bacterium
mixture was plated on CT-SMAC. Samples that resulted
culture-positive by IMS were considered positive (10 CFU),
while samples culture-negative by IMS were deemed nega-
tive. Non-sorbitol-fermenting colonies were tested for E. coli
O157 LPS by latex agglutination (Oxoid, Basingstoke, UK)
and confirmed by a multiplex PCR for the stx1, stx2, eae, and
rfbO157 genes [26–28]. Tissues obtained at necropsy were
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cultured to detect E. coli O157:H7 after IMS as described
above.
2.6. Production of Recombinant E. coli O157:H7 Proteins.
EspB and 𝛾-intimin C280 genes from the E. coli O157:H7
strain 146N were cloned in pRSET-A vector (Invitro-
gen Corp., Carlsbad, CA) and expressed in E. coli BL21
(D3)/pLysS, as described previously [29]. The amino-
terminal-His-tagged proteins were purified from the lysates
by affinity chromatography on nickel-agarose columns
(ProBond nickel-chelating resin; Invitrogen Corp.), eluted
under denaturing conditions, and dialyzed in PBS at pH 7.4.
2.7. Antibody Response. All sera samples taken before and
during the experiment were analyzed by ELISA to detect spe-
cific antibodies againstE. coliproteins EspB and 𝛾280-intimin
as described elsewhere [29]. Briefly, 96-well Nunc-Immuno
MaxiSorp assay plates (Nunc, Roskilde, Denmark) were
coated overnight at 4∘C with 100𝜇L of either 𝛾280-intimin
or EspB at 1 𝜇g/mL in carbonate buffer pH 9.6. After three
washes with PBS pH 7.4 containing 0.05% Tween 20 (PBS-
T), nonspecific binding sites were blocked with 3% skimmed
milk in PBS for 1 h at 37∘C. After that, washes were repeated,
and sera diluted 1/50 in PBS-T were added (100 𝜇L/well).
Plates were incubated for 2 h at 37∘C. For each plate, two
wells were incubated with PBS-T alone (negative control),
and a known positive sample was included. Each sample was
analyzed in duplicate. After washing with PBS-T, wells were
incubated for another hour with 100 𝜇L of sheep anti-bovine
IgG, IgG1, IgG2, or IgA conjugated with horseradish perox-
idase (Bethyl Laboratories, Montgomery, USA), at dilutions
of 1 : 10000 in PBS-T. Plates were washed three times with
PBS-T. Finally, ABTS [2,2-azino-di (3-ethyl-benzthiazoline
sulphonic acid)] (Amresco, Solon, USA) in citrate-phosphate
buffer pH 4.2 plus 0.01% H
2
O
2
(100 𝜇L/well) was added.
Reactions were stopped after 10min with 100 𝜇L/well of
5% SDS and read at 405 nm (OD
405
) in a BioTek ELx808
microplate reader (BioTek Instruments, Winooski, USA).
Mucosal antibodies from intestinal tissue samples taken at
necropsy were obtained as described elsewhere [30] and
assessed by ELISA for the presence of specific antibodies as
described above. The specificity of antibodies was confirmed
by Western blot.
2.8. Histopathological Examination. One segment of ileum,
cecum, and rectoanal junction (approximately 20 g each)
from each animal was obtained at necropsy and immediately
fixed in neutral buffered 10% formalin, dehydrated with
alcohol, and embedded in paraffin. Sagittal cuts (5 𝜇m) were
made with a microtome (Leica RM 2125, Wetzlar, Germany),
stained with hematoxylin and eosin (H&E), and mounted
on 2% silane-coated slides. Tissue sections were observed by
light microscopy (Nikon Eclipse 200, NY, USA).
2.9. Immunohistochemistry. Immunohistochemistry was
performed on tissue segments that were positive for E.
coli O157:H7 culture, as described above. Briefly, dewaxed
sections were blocked for endogenous peroxidase with H
2
O
2
3% inmethanol for 10min. Later, the slideswere preincubated
with no immune rabbit serum at room temperature for
30min. Then, the primary rabbit anti-O157 LPS antibody,
which was kindly provided by Susana Bruno (Antisera
Service (ANLIS, Argentina)), was added (1 : 100).The sections
were incubated with the primary antibody in a humidity
chamber at 4∘C overnight.The immunoperoxidase technique
was then performed following the protocol from the RTU
Vectastain Kit (Vector, Peterborough, UK). The antigen was
revealed by diaminobenzidine (DAB, Vector). Finally, the
sections were counterstained by Meyer’s Hematoxylin and
mounted for observation. Specificity tests were performed
by omitting the primary antiserum in the staining.
2.10. Statistical Analysis. Data analyzed were bacterial shed-
ding of calves and levels of antibodies. To attain normality,
both set of variables were transformed using procedures
described byBox andCox [31].The transformation parameter
was obtained after a grid search in the open interval (−0.95,
0.95). Resulting variables were analyzed using linear models
for repeated measures [32], as in Vilte et al. [22, 23].
For the transformed CFU (TCFU) variable describing
the shedding of calves effects in the model were dose of E.
coli O157:H7 (as a classification variable with two levels:
108 and 1010 CFU), the covariate initial level of antibodies
nested within dose (i.e., one covariate per dose), and a linear
term for the covariate day of measure interacting with dose,
so as to account for the daily trend within treatment. The
dependence structure among repeated measures within
animal within dose was modeled with a Gaussian covariance
matrix. The area under the curve (AUC) was obtained using
estimable linear functions [33]. The hypothesis of interest
was whether the estimated AUC from the two doses differ at
different times (14 and 28 days), and including or excluding
the effect of the initial antibody level. All tests of hypotheses
had their degrees of freedom corrected by the procedure
of Kenward and Roger [34], and 𝑝 values smaller than 0.05
were considered to be significant.
Differences in antibodies were tested from either
estimable contrasts or differences in least-square means [33].
Models used included different effects according to antibody.
In all cases, the residual covariance structure was 4-banded
Toeplitz for the four different measures, within animal. All
analyses were performed using Proc Mixed of SAS version
9.2 (SAS, 2013).
3. Results
3.1. E. coli O157:H7 Shedding after Challenge. In order to
observe the effect of challenge dose on total shedding and
kinetics of E. coli O157:H7, two groups of calves were orally
challenged either with 108 or with 1010 CFUof E. coliO157:H7.
The kinetics of fecal shedding in both groups is shown in
Figure 1. To understand if there is a relationship between
dose and fecal shedding, we performed a statistical analysis
using a linear model for repeated measures (SAS) analysis
(Table 1). All main effects and covariates displayed a highly
significant effect on TCFU: dose 1010 produced more TCFU
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Figure 1: Shedding pattern of calves inoculated with either 108 or
1010 CFU of E. coli O157:H7. Data are shown as log CFU/swab ±
S.E.M.
than 108. For the covariable anti-𝛾-intimin C280 antibody
(dose), the higher the level of antibodies the smaller the
number of TCFU. Finally, the linear covariate dose by
day showed smaller levels as the days passed. Cubic and
quadratic responses (not shown in Table 1) were far from
being significant. When anti-EspB antibodies were used as
covariable, no significant effect of the TCFU was observed.
The results of the tests of hypothesis of differences in AUC by
dose are displayed in Table 2. All tests produced significant
differences in AUC due to dose and day (14 or 28).
Therewas a significant difference in shedding between the
groups. The calves that received 108 CFU shed fewer bacteria
for 14 days as well as 28 days, compared to the ones that
were challengedwith 1010 CFU.When the levels of preexisting
IgG antibodies against 𝛾-intiminC280were considered in the
model, the difference became even more significant (see 𝑝
values in Table 2).
One animal from each group was excreting E. coli
O157:H7 on day 28 after the challenge, and the challenge
strain was isolated from rectoanal junction tissue obtained
from these animals at necropsy. The bacterium was also
detected by immunohistochemistry (see below).
3.2. Humoral Immune Response to E. coli O157:H7 Challenge.
Serum IgG and IgA antibodies were assessed by ELISA on the
day of E. coli O157:H7 challenge (0 dpc) and at different time
points after the challenge. Results are shown in Figure 2. As
expected, specific IgG was higher than IgA for both antigens
tested. Furthermore, most of the IgG was IgG1, whereas IgG2
was very low (data not shown). Higher OD
405
values were
obtained for IgG antibodies against EspB than against 𝛾-
intimin C280, and these levels were very similar for both
groups.
IgA response against any of the antigens was not detected
in the group that received 1010 CFU whereas the level of IgA
specific for both antigens rose in the calves challenged with
the lowest dose reaching, at day 8 after the challenge, levels
similar to those of IgG. In spite of this, the difference was not
statistically significant.
No neutralizing activity against Stx2 was observed (data
not shown).
3.3. Mucosal Immune Response to E. coli O157:H7 Challenge.
Specific mucosal IgG and IgA antibodies were assessed in
tissue segments of rectoanal junction, ileum, and cecum.
Results are shown in Figure 3.
IgG against both EspB and 𝛾-intimin C280 was found
significantly higher than IgA in both groups in the three
segments assessed (𝑝 < 0.0001).
IgG and IgA antibodies against EspB were significantly
higher in RAJ and cecumofGroup 2 than inGroup 1, whereas
no significant differences were found in antibodies against 𝛾-
intimin C280 between groups.
3.4. Histopathology. Upon histopathological examination,
ileum and cecum from Groups 1 and 2 presented histological
signs of inflammation and mild epithelial necrosis with
detachment of the surface epithelium (Figure 4 Supplemen-
tary Material, in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/290679). Taking into account
that the preferential attachment site of the bacteria is the
rectoanal junction, it is important to mention that a normal
histoarchitecture with polymorphonuclear leukocytes infil-
trations was observed in this tissue (Figure 4 Supplementary
Material).
3.5. Immunohistochemistry. E. coli O157:H7 was detected by
using an antibody against O157 in segments of rectoanal
junction of two calves that continued to excrete at day 28 after
inoculation (Figure 5 Supplementary Material).
4. Discussion
During this study, two groups of randomly assigned calves
were intragastrically challenged with either 108 or 1010 CFU
of E. coli O157:H7. We observed a statistically significant
difference in the area under the shedding curves between the
two doses of bacterial challenge used in this study for both 14
and 28 days, the group that received the lower dose being the
one that shed less bacteria, suggesting a relationship between
the challenge dose and the bovine intestinal colonization.
Furthermore, when the preexisting antibodies against 𝛾-
intimin C280 were included in the model, this difference
became even more significant. This finding suggests that
previous antibodies against this protein could partially reduce
E. coli O157:H7 carriage in calves.
Intimin has been shown to be a target of humoral immune
responses in different host species and animal models such as
humans [35–37], cattle [16, 20–23, 29], rabbits [24], pigs [38],
and mice [39, 40]. These antibodies have been proved to be
effective in avoiding epithelial colonization by E. coliO157:H7
[41] and can be obtained through vaccination [20–23] as well
as experimental infections [22, 23]. However, this response is
not completely protective since animals continue to excrete
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Figure 2: IgG ((a), (b)) and IgA ((c), (d)) antibodies against 𝛾-intimin C280 ((a), (c)) and EspB ((b), (d)) in calves challenged with 108 or
1010 CFU of E. coli O157:H7. Data are shown as mean OD405 ± S.E.M.
Table 1: Tests of the effects into the model for transformed CFU.
Effect Numerator df Denominator df 𝐹-value Pr < 𝐹
Dose 2 36.4 57.63 <0.0001
Anti-𝛾-intimin C280
antibody (dose) 2 33.5 8.58 0.0010
Anti-EspB
antibody (dose) 2 35.4 0.72 0.4944
Day × dose 2 40.4 16.77 <0.0001
Table 2: Test of hypotheses on differences of areas under the curve for different doses and at different days.
Null hypothesis Covariate level ofantibody considered Day Result of the estimate 𝑝 value
AUC 1 = AUC 2 No 14 AUC 1 < AUC 2 0.0069
AUC 1 = AUC 2 Yes 14 AUC 1 < AUC 2 0.0056
AUC 1 = AUC 2 No 28 AUC 1 < AUC 2 0.0209
AUC 1 = AUC 2 Yes 28 AUC 1 < AUC 2 0.0185
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Figure 3: Mucosal IgG and IgA antibodies against EspB and 𝛾-intimin C280 in calves challenged with 108 or 1010 CFU of E. coli O157:H7.
Data are shown as mean OD405 ± S.E.M.
the bacteria despite a reduction in shedding and can be
reinfected. In the present conditions, we cannot differentiate
if the preexisting antibodies against 𝛾-intimin C280 came
from passive immunization through colostrum from their
mothers after birth or from the fact that animals were infected
by EHEC in the field.
During this study, we did not observe a statistically sig-
nificant increase in serum antibodies after challenge against
any of the antigens tested. However, there was a difference
between IgG and IgA antibodies, which could be explained
considering that IgG concentration in bovine serum is higher
than IgA and has a longer half-life [42, 43].
Interestingly, no IgA response was detected against either
EspB or 𝛾-intimin C280 in the serum of calves from Group
2. Naylor et al. [17] have demonstrated that young calves
develop serum IgG and IgA antibody responses to O157
and H7, and the IgA but not IgG titers decreased after
colonization following a repeated challenge. Furthermore, it
was found [16] that the IgA titers decreased only to factors
having a known (Eae and Tir) or highly probable function
in colonization (EspB), whereas those to O157 increased.
These results suggest that serum IgA antibodies against
virulence factors involved in colonization may be consumed
in response to challenge.
A mild mucosal immune response was observed in
both groups in response to E. coli O157 challenge, with
higher IgG than IgA antibody levels, as expected, since this
immunoglobulin predominates in the mucosa of ruminants
[44]. Significantly higher levels of IgG and IgA antibodies
against EspB were found in RAJ and cecum of the calves
that received the higher dose of bacteria. Interestingly, these
animals had very low levels of IgA antibodies in serum.
These results suggest that the challenge dose influences
the colonization rate and the immune response elicited, at
least, in some mucosal epitheliums. Nart et al. [30] have
shown that the E. coli O157:H7 colonization induces a local
mucosal antibody response, which is directed at several
membrane-associated and secreted proteins. Similarly, adult
cattle develop colonic and rectal mucosal antibodies of the
IgG and IgA classes to E. coli O157:H7 antigens following
experimental infection; however, these titers are low [16].This
could be explained by the evidence provided by Hoffman
et al. [45] who suggested that Stx2 produced by E. coli
O157:H7 during the course of infection may reduce lympho-
proliferative responses in intraepithelial as well as peripheric
lymphocytes. By contrast, the strain used in our study was
Stx2+.Therefore, its immunosuppressive effect must be taken
into account since it could explain the low mucosal antibody
response that was observed. It would be interesting to further
study this response in other mucosal sites such as saliva or
nasal swabs.
This study has led us to conclude that the dose of
experimental challenge with E. coli O157:H7 influences the
colonization rate on the bovine intestinal tract and that preex-
isting antibodies against 𝛾280-intimin may have a protective
role against colonization. We have also concluded that oral
experimental challenge with a Stx2+ strain induces a mild
mucosal immune response.
This finding suggests a relationship between coloniza-
tion, shedding, and immunity. Although further studies are
required to elucidate the role of antibodies and cellular
immunity in the excretion dynamics of E. coli O157:H7, the
enhancement of immune responses can be proposed as a
potential prophylactic measure to control bovine carriage of
E. coli O157:H7.
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